Health Novel Anti-CD20 Drug Shows Promise in Relapsing MS Jason Junior Oct 15, 2021 Ublituximab, an investigational monoclonal antibody targeting CD20, lowered relapse rates relative to teriflunomide (Aubagio) in two identical phase III trials of people with…
